Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples